Neogen Chemicals Q1 FY27 Revenue Up 34% to ₹250 Crore, PAT Rises 67% to ₹17.1 Crore
Neogen Chemicals reported Q1 FY27 consolidated revenue of ₹250.3 crore, up 34% YoY. PAT increased 67% to ₹17.1 crore. The company received board approval to raise up to ₹600 crore via QIP. Dahej plant reconstruction is complete, and battery materials projects are on track.
The strong financial performance, progress on strategic expansion projects (especially in the high-growth battery materials segment), and a significant equity raise signal substantial positive developments for the company's future growth and operational capacity.
The company reported significant year-on-year growth in revenue and profit, along with positive updates on plant reconstruction, expansion projects, and a substantial fund-raising approval.
Neogen Chemicals Limited announced its unaudited financial results for the quarter ended June 30, 2026 (Q1 FY27). The company reported a consolidated revenue of ₹250.3 crore, marking a 34% increase compared to ₹186.7 crore in Q1 FY26. Consolidated EBITDA grew by 53% to ₹48.2 crore, with EBITDA margins improving to 19.3% from 16.9% in the prior year quarter.
Consolidated Profit After Tax (PAT) surged by 67% to ₹17.1 crore, up from ₹10.3 crore in Q1 FY26, with PAT margins expanding to 6.8% from 5.5%. On a standalone basis, revenue increased by 37% to ₹252.3 crore, and PAT grew by 37% to ₹19.4 crore.
The company highlighted strong revenue growth driven by higher volumes in key product lines, particularly the Organolithium portfolio. Neogen Ionics (NIL) contributed ₹19 crore in revenue for Q1 FY27, a significant increase from ₹5 crore in Q1 FY26. Despite global headwinds and increased input costs, the company managed to protect operating margins through cost pass-throughs and a favorable product mix. Higher finance costs were noted due to increased debt drawdown for CAPEX and working capital intensity.
Key updates include the completion of the Dahej plant reconstruction, with trial runs underway. The company also announced board approval for raising up to ₹600 crore through a Qualified Institutional Placement (QIP). Cumulative insurance claim recoveries stand at ₹164 crore, with a further tranche of ₹15 crore received in July 2026.
Expansion initiatives for Neogen Ionics' Battery Materials projects are on schedule, with an estimated project cost of ₹1,795 crore. The Dahej Phase 1 project is targeted for completion by February 2027, and Pakhajan Phase 2 by March 2027.
Dr. Harin Kanani, Managing Director, stated that FY27 will be a defining year for commissioning and scaling up the battery materials project. He reaffirmed the company's focus on executing its CAPEX roadmap and unlocking operating leverage for sustainable growth. The company also secured the EcoVadis Silver Medal for 2026, underscoring its commitment to ESG.
What to do with a filing like this
Neogen Chemicals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Neogen Chemicals Limited. Read the original for the full detail.